摘要
目的 探讨浸润性乳腺癌的近似分子分型、临床病理特征及其意义.方法 回顾分析326例乳腺癌的临床病理资料,用免疫组化EnVision法检测ER、PR、Her-2和Ki-67.根据免疫组化结果将乳腺癌划分为管腔上皮A型（LuminalA型）、管腔上皮B型（LuminalB型）、Her-2过表达型和基底细胞样型（Basal-like型）4型,其中LuminalB型根据Ki-67表达情况分为2个亚型,即Her-2（-）（Ki-67≥14％）和Her-2（＋）（Ki-67为任意水平）.比较各型乳腺癌的免疫表达、分布比例、发病年龄、病理分级以及治疗方法.结果 326例浸润性乳腺癌中,LuminalA型151例（46.3％）,LuminalB型63例（19.3％）,其中Her-2（-）的LuminalB型17例;Her-2过表达型52例（16％）;Basal-like型60例（18.4％）.所有患者均为女性,年龄28～45岁者96例,46～ 68岁者230例.病理分级1级者中LuminalA型比例最高;3级者中Basal-like型比例最高.结论 采用免疫组化技术检测ER、PR、Her-2和Ki-67对乳腺癌进行近似分子分型,简单实用,适宜推广,并对该病的治疗更具有针对性.
Objective To study the approximate molecular typing of invasive breast cancer, clinical pathological characteristics and significance. Methods The clinical and pathological data of 326 cases were analyzed retrospectively. We used immunohistochemieal （IHC） technique （EnVision method） to examine the expression of ER, PR, HER2 and Ki- 67. All the cases were categorized into four different subtypes： luminal A, luminal B, HER2 overexpressing and basal-like cases and their IHC markers, distribution, age grading and therapy methods were analyzed, respectively. In luminal B, there were two subtypes based on the expression of Ki-67 markers ： one was negative HER2, Ki-67 I〉 14% cases, and another was HER2-positive cases. Results A total of 326 cases of invasive breast cancer, luminal A type was 46.3 % , luminal B was 19.3% , HER2 ＋ was 15.9% and Basal-like was 18.4%. The age of 96 cases among all female patients ranged from 28 to 45 years old, and the rest 46 to 68 years old. Luminal A was more than others among grading 1 tumors ; basal-like was more than others among grading 3 tumors. Conelution The classification of approximate molecular subtypes of breast cancer defined by IHC markers is feasible and suitable for promotion. This classification makes our understanding of breast cancer deeper and treatment more targeted.
出处
《诊断病理学杂志》
CSCD
北大核心
2014年第12期747-750,共4页
Chinese Journal of Diagnostic Pathology
关键词
乳腺癌
分子分型
临床病理特征
免疫组化
Breast cancer
Molecular subtype
Clinieopathological characteristics
Immunohistochemistry
